Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia A

PHASE3CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Congenital Hemophilia A
Interventions
BIOLOGICAL

rVIII-SingleChain

Trial Locations (37)

1090

Study Site, Vienna

3052

Study Site, Melbourne

4020

Study Site, Linz

6000

Study Site, Cebu City

Study Site, Lucerne

8000

Study Site, Davao City

10330

Study Site, Bangkok

10700

Study Site, Bangkok

20122

Study Site, Milan

28046

Study Site, Madrid

28177

Study Site, Bremen

29609

Study Site, Brest

30159

Study Site, Hanover

34098

Study Site, Istanbul

35100

Study Site, Izmir

40002

Study Site, Khon Kaen

44093

Study Site, Nantes

50200

Study Site, Chiang Mai

50400

Study Site, Kuala Lumpur

53127

Study Site, Bonn

59037

Study Site, Lille

60590

Study Site, Frankfurt am Main

60612

Study Site, Chicago

75015

Study Site, Paris

79044

Study Site, Lviv

80045

Study Site, Aurora

90110

Study Site, Songkhla

94270

Study Site, Le Kremlin-Bicêtre

300011

Study Site, Timișoara

11072240

Study Site, Beirut

0177

Study Site, Tbilisi

1105 AZ

Study Site, Amsterdam

6525 GA

Study Site, Njmegen

3584 CX

Study Site, Utrecht

35-310

Study Site, Rzeszów

4202-451

Study Site, Porto

01330

Study Site, Adana

Sponsors

Lead Sponsor

All Listed Sponsors
lead

CSL Behring

INDUSTRY

NCT02093897 - Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia A | Biotech Hunter | Biotech Hunter